This year marks the tenth anniversary of cell therapy with chimeric antigen receptor (CAR)-
modified T cells for refractory leukemia. The widespread commercial approval of genetically …

The T cell receptor (TCR) complex is a naturally occurring antigen sensor that detects,
amplifies and coordinates cellular immune responses to epitopes derived from cell surface …

The accepted paradigm for both cellular and anti-tumor immunity relies upon tumor cell
killing by CD8+ T cells recognizing cognate antigens presented in the context of target cell …

Somatic gene mutations can alter the vulnerability of cancer cells to T-cell-based
immunotherapies. Here we perturbed genes in human melanoma cells to mimic loss-of …

Although mutations may represent attractive targets for immunotherapy, direct identification
of mutated peptide ligands isolated from human leucocyte antigens (HLA) on the surface of …

Nine cancer patients were treated with adoptive cell therapy using autologous anti-MAGE-
A3 T-cell receptors (TCR)-engineered T cells. Five patients experienced clinical regression …

A major obstacle for chimeric antigen receptor (CAR) T cell therapy in solid tumors is the
lack of truly tumor-specific target antigens, which translates to the targeting of tumor …

Chimeric antigen receptor (CAR) gene-engineered T cell therapy holds the potential to
make a meaningful difference in the lives of patients with terminal cancers. For decades …

Advances in cell-based therapy, particularly CAR-T cell therapy, have transformed the
treatment of hematological malignancies. Although an important step forward for the field …

Gamma delta T (γδT) lymphocytes are primed for rapid function, including cytotoxicity toward
cancer cells, and are a component of the immediate stress response. Following activation …